☰

Peter Gibbs - Publications

Affiliations: 
mskcc, New York, NY, United States 
Area:
mri
Tree Info Similar researchers PubMed Report error

98 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Piercey O, Wong HL, Leung C, To YH, Heong V, Lee M, Tie J, Steel M, Yeung JM, McCormick J, Gibbs P, Wong R. Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence. Clinical Colorectal Cancer. PMID 38242766 DOI: 10.1016/j.clcc.2024.01.001  0.362
2023 Mattox AK, Douville C, Wang Y, Popoli M, Ptak J, Silliman N, Dobbyn L, Schaefer J, Lu S, Pearlman AH, Cohen JD, Tie J, Gibbs P, Lahouel K, Bettegowda C, et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discovery. PMID 37565753 DOI: 10.1158/2159-8290.CD-21-1252  0.307
2023 Loft M, To YH, Gibbs P, Tie J. Clinical application of circulating tumour DNA in colorectal cancer. The Lancet. Gastroenterology & Hepatology. 8: 837-852. PMID 37499673 DOI: 10.1016/S2468-1253(23)00146-2  0.313
2023 Conduit C, Lewin J, Weickhardt A, Lynam J, Wong S, Grimison P, Sengupta S, Pranavan G, Parnis F, Bastick P, Campbell D, Hansen AR, Leonard M, McJannett M, Stockler MR, ... Gibbs P, et al. Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. Jco Oncology Practice. OP2300191. PMID 37327464 DOI: 10.1200/OP.23.00191  0.326
2022 To YH, Degeling K, McCoy M, Wong R, Jones I, Dunn C, Hong W, Loft M, Gibbs P, Tie J. Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer. Asia-Pacific Journal of Clinical Oncology. PMID 36464923 DOI: 10.1111/ajco.13885  0.339
2022 Loft M, Shapiro J, Lee M, Wong R, Tie J, Kosmider S, Wong V, Jalali A, Lee B, Ananda SS, Gibbs P. Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer. Internal Medicine Journal. PMID 35668542 DOI: 10.1111/imj.15835  0.317
2022 Downie JM, Riaz M, Xie J, Lee M, Chan AT, Gibbs P, Orchard SG, Mahady SE, Sebra RP, Murray AM, Macrae F, Schadt E, Woods RL, McNeil JJ, Lacaze P, et al. Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. Cancer Prevention Research (Philadelphia, Pa.). PMID 35609203 DOI: 10.1158/1940-6207.CAPR-22-0080  0.309
2022 Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. The Lancet. Oncology. PMID 35427471 DOI: 10.1016/S1470-2045(22)00197-8  0.328
2021 Dunn C, Hong W, Gibbs P, Ackland S, Sjoquist K, Tebbutt NC, Price T, Burge M. Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clinical Colorectal Cancer. PMID 34103264 DOI: 10.1016/j.clcc.2021.05.001  0.319
2021 Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, Wong HL, Kosmider S, Wong R, Thomson B, Choi J, Fox A, Field K, Burge M, Shannon J, ... ... Gibbs P, et al. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. Plos Medicine. 18: e1003620. PMID 33939694 DOI: 10.1371/journal.pmed.1003620  0.309
2021 Min ST, Roohullah A, Tognela A, Jalali A, Lee M, Wong R, Shapiro J, Burge M, Yip D, Nott L, Zimet A, Lee B, Dean A, Steel S, Wong HL, ... Gibbs P, et al. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population. Asia-Pacific Journal of Clinical Oncology. PMID 33870631 DOI: 10.1111/ajco.13553  0.332
2021 Kostos L, Hong W, Lee B, Tran B, Lok SW, Anton A, Gard G, To YH, Wong V, Shapiro J, Wong R, Wong S, De Boer R, Gibbs P. Cancer Clinical Trial Versus Real-World Outcomes for Standard of Care First-Line Treatment in the Advanced Disease Setting. International Journal of Cancer. PMID 33729581 DOI: 10.1002/ijc.33568  0.346
2021 Naidoo M, Gibbs P, Tie J. ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm. Cancers. 13. PMID 33477814 DOI: 10.3390/cancers13020346  0.363
2021 Kalapurackal Mathai V, Aung SY, Wong V, Dunn C, Shapiro JD, Jalali A, Wong R, Lee M, Tie J, Ananda S, Kosmider S, Lim SH, Caird S, Burge ME, Dean AP, ... Gibbs P, et al. Outcomes of isolated distant lymph node metastases in colorectal cancer. Journal of Clinical Oncology. 39: 84-84. DOI: 10.1200/JCO.2021.39.3_SUPPL.84  0.306
2021 Jalali A, Wong H, Wong R, Lee M, Gately L, Loft M, Shapiro JD, Kosmider S, Tie J, Ananda S, Yeung J, Jennens R, Lee B, McKendrick JJ, Lim L, ... ... Gibbs P, et al. Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer. Journal of Clinical Oncology. 39: 71-71. DOI: 10.1200/JCO.2021.39.3_SUPPL.71  0.308
2021 Alidina A, Lipton LR, Gately L, Skinner I, Mendis SR, Hong W, Dunn C, Cho J, To YH, Steel M, Jones I, Lee M, Tie J, Kosmider S, Wong R, ... ... Gibbs P, et al. Second primary cancers in patients with sporadic deficient mismatch repair (dMMR) colorectal cancer (CRC). Journal of Clinical Oncology. 39: 45-45. DOI: 10.1200/JCO.2021.39.3_SUPPL.45  0.346
2020 Foroughi S, Wong HL, Tie J, Wong R, Lee M, Lee B, Jones I, Skinner I, Burgess AW, Gibbs P. Characteristics and outcomes of participants in colorectal cancer biomarker trials versus a real-world cohort. Acta Oncologica (Stockholm, Sweden). 1-9. PMID 33377792 DOI: 10.1080/0284186X.2020.1862907  0.355
2020 To YH, Lee B, Wong HL, Gibbs P, Tie J. Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies. Visceral Medicine. 36: 388-396. PMID 33178736 DOI: 10.1159/000509657  0.303
2020 Travers A, Jalali A, Begbie S, Semira C, Kosmider S, Ananda S, Wong R, Lee M, Shapiro J, Burge M, Yip D, Torres J, Ma B, Nott L, Dean A, ... ... Gibbs P, et al. Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. Clinical Colorectal Cancer. PMID 32919889 DOI: 10.1016/j.clcc.2020.08.002  0.345
2020 Luo MJ, Palmieri M, Riffkin CD, Sakthianandeswaren A, Djajawi TM, Hirokawa Y, Shuttleworth V, Segal DH, White CA, Nhu D, Lessene G, Lee M, Gibbs P, Huang DCS, Sieber OM, et al. Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. Cell Death & Disease. 11: 735. PMID 32913182 DOI: 10.1038/s41419-020-02815-0  0.333
2020 Prasanna T, Wong R, Price T, Shapiro J, Tie J, Wong HL, Nott L, Roder D, Lee M, Kosmider S, Jalali A, Burge M, Padbury R, Maddern G, Carruthers S, ... ... Gibbs P, et al. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Current Problems in Cancer. 100637. PMID 32826083 DOI: 10.1016/j.currproblcancer.2020.100637  0.311
2020 Degeling K, Wong HL, Koffijberg H, Jalali A, Shapiro J, Kosmider S, Wong R, Lee B, Burge M, Tie J, Yip D, Nott L, Khattak A, Lim S, Caird S, ... Gibbs P, et al. Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics. PMID 32803720 DOI: 10.1007/s40273-020-00951-1  0.307
2020 Clarke SJ, Burge M, Feeney K, Gibbs P, Jones K, Marx G, Molloy MP, Price T, Reece WHH, Segelov E, Tebbutt NC. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. Plos One. 15: e0229900. PMID 32142532 DOI: 10.1371/journal.pone.0229900  0.377
2020 Kumari S, Semira C, Lee M, Lee B, Wong R, Nott L, Shapiro J, Gibbs P. Resection of colorectal cancer liver metastases in older patients. Anz Journal of Surgery. PMID 32072725 DOI: 10.1111/ans.15750  0.327
2020 Yoshino T, Kim T, Yong W, Shiu K, Jensen BV, Jensen LH, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, Fouchardiere Cdl, Rivera F, Elez E, Bendell J, Le D, et al. 112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study Annals of Oncology. 31: S1284-S1285. DOI: 10.1016/j.annonc.2020.10.132  0.31
2019 Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, Lee B, Cho JH, Faragher I, Jones IT, Ptak J, ... ... Gibbs P, et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. Jama Oncology. PMID 31621801 DOI: 10.1001/Jamaoncol.2019.3616  0.323
2019 Williams DS, Mouradov D, Browne C, Palmieri M, Elliott MJ, Nightingale R, Fang CG, Li R, Mariadason JM, Faragher I, Jones IT, Churilov L, Tebbutt NC, Gibbs P, Sieber OM. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31471586 DOI: 10.1038/S41379-019-0353-2  0.335
2019 Wang Y, Li L, Cohen JD, Kinde I, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tie J, Gibbs P, Tomasetti C, Kinzler KW, Papadopoulos N, Vogelstein B, et al. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. Jama Oncology. PMID 31070668 DOI: 10.1001/Jamaoncol.2019.0512  0.329
2019 Lee B, Gibbs P. Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. Journal of Personalized Medicine. 9. PMID 31035449 DOI: 10.3390/jpm9020020  0.312
2019 Mendis S, Beck S, Lee B, Lee M, Wong R, Kosmider S, Shapiro J, Yip D, Steel S, Nott L, Jennens R, Lipton L, Burge M, Field K, Ananda S, ... ... Gibbs P, et al. Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. Asia-Pacific Journal of Clinical Oncology. PMID 30761750 DOI: 10.1111/ajco.13135  0.309
2019 Jorissen RN, Croxford M, Jones IT, Ward RL, Hawkins NJ, Gibbs P, Sieber OM. Evaluation of the Transferability of Survival Calculators for Stage II/III Colon Cancer Across Healthcare Systems. International Journal of Cancer. PMID 30620048 DOI: 10.1002/ijc.32100  0.3
2019 Mendis SR, Lee B, Lee M, Wong R, Kosmider S, Shapiro JD, Yip D, Steel SA, Nott LM, Jennens R, Lipton LR, Burge ME, Field KM, Ananda S, Beck S, ... ... Gibbs P, et al. Left- versus right-side metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. Journal of Clinical Oncology. 37: 623-623. DOI: 10.1200/JCO.2019.37.4_suppl.623  0.336
2019 Chan AT, Gibbs P, Lockery JE, Polekhina G, Orchard SG, Ford L, Umar A, McNeil jJ. EFFECT OF INITIATING ASPIRIN ON CANCER EVENTS IN THE HEALTHY ELDERLY Innovation in Aging. 3: S633-S633. DOI: 10.1093/geroni/igz038.2358  0.313
2018 Sud S, O'Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, Van Hazel G, Pavlakis N, Gibbs P, Jeffrey M, Siu L, Gill S, Wong R, Jonker D, et al. Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. Current Oncology (Toronto, Ont.). 25: e516-e526. PMID 30607118 DOI: 10.3747/co.25.4069  0.364
2018 Semira C, Wong HL, Field K, Lee M, Lee B, Nott L, Shapiro J, Wong R, Tie J, Tran B, Richardson G, Zimet A, Lipton L, Tamjid B, Burge M, ... ... Gibbs P, et al. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence? Internal Medicine Journal. PMID 30230679 DOI: 10.1111/imj.14115  0.321
2018 Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, et al. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet. Gastroenterology & Hepatology. PMID 30042065 DOI: 10.1016/S2468-1253(18)30117-1  0.334
2018 Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, et al. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncologica (Stockholm, Sweden). 1-7. PMID 30035653 DOI: 10.1080/0284186X.2018.1487581  0.305
2018 Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J. Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy. PMID 30019590 DOI: 10.1080/14737140.2018.1502664  0.303
2018 Lee MM, MacKinlay A, Semira C, Schieber C, Jimeno Yepes AJ, Lee B, Wong R, Hettiarachchige CKH, Gunn N, Tie J, Wong HL, Skinner I, Jones IT, Keck J, Kosmider S, ... ... Gibbs P, et al. Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. Clinical Colorectal Cancer. PMID 29980491 DOI: 10.1016/j.clcc.2018.05.008  0.305
2018 Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy. PMID 29478352 DOI: 10.1080/14737140.2018.1444481  0.345
2018 Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsaleh H, Kosmider S, Wong R, Yip D, Lee M, Tran B, Rangiah D, Burge M, Goldstein D, ... ... Gibbs P, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. PMID 29420226 DOI: 10.1136/Gutjnl-2017-315852  0.318
2018 Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, ... ... Gibbs P, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science (New York, N.Y.). PMID 29348365 DOI: 10.1126/Science.Aar3247  0.301
2017 Wasan H, van Hazel G, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M, Findlay M, Virdee PS, Love S, Moschandreas J, Dutton P, Gebski V, Gray A, Price D, ... ... Gibbs P, et al. Overall survival analysis of the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii148. PMID 32135786 DOI: 10.1093/annonc/mdx262.026  0.314
2017 Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet. Oncology. PMID 28781171 DOI: 10.1016/S1470-2045(17)30457-6  0.328
2017 Virdee PS, Moschandreas J, Gebski V, Love SB, Francis EA, Wasan HS, van Hazel G, Gibbs P, Sharma RA. Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer. Jmir Research Protocols. 6: e43. PMID 28351831 DOI: 10.2196/resprot.7201  0.306
2017 Au L, Turner N, Wong HL, Field K, Lee B, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, ... ... Gibbs P, et al. How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia? Asia-Pacific Journal of Clinical Oncology. PMID 28299879 DOI: 10.1111/ajco.12671  0.335
2017 Lee B, Anton A, Lee M, Wong R, Parente P, Shapiro JD, Yip D, Steel SA, Nott LM, Stefanou G, Iddawela MY, Gibbs P, Tran B. Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 35: 728-728. DOI: 10.1200/JCO.2017.35.4_suppl.728  0.318
2017 Papadopoulos N, Wang Y, Cohen J, Hruban R, Gibbs P, Tie J, Diaz L, Kinzler K, Vogelstein B. Abstract IA17: Non-invasive detection of somatic mutations in the management of CRC Cancer Research. 77. DOI: 10.1158/1538-7445.Crc16-Ia17  0.347
2017 Sharma N, van Hazel G, Findlay M, Ricke J, Peeters M, Gebski V, van Buskirk M, Gibbs P, Heinemann V. Using data from the SIRFLOX study to evaluate depth of response within a volumetric model in patients with metastatic colorectal cancer Journal of Vascular and Interventional Radiology. 28: S160-S161. DOI: 10.1016/J.JVIR.2016.12.993  0.31
2016 Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva G, Novotny J, O'Reilly S, Salek T, Reiner M, Morrow PK, Choi MR, et al. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clinical Colorectal Cancer. PMID 28038865 DOI: 10.1016/j.clcc.2016.08.008  0.3
2016 Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, ... ... Gibbs P, et al. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer. PMID 27780749 DOI: 10.1016/j.clcc.2016.08.005  0.308
2016 Daniel ES, Dean AE, Lim M, Master M, Gibbs P, Faragher I. Incidence of pulmonary embolism in patients with newly diagnosed colorectal cancer. Anz Journal of Surgery. PMID 27723238 DOI: 10.1111/ans.13789  0.318
2016 Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, ... ... Gibbs P, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine. 8: 346ra92. PMID 27384348 DOI: 10.1126/Scitranslmed.Aaf6219  0.312
2016 Sammour T, Hayes IP, Jones IT, Steel MC, Faragher I, Gibbs P. Impact of anastomotic leak on recurrence and survival after colorectal cancer surgery: a BioGrid Australia analysis. Anz Journal of Surgery. PMID 27255690 DOI: 10.1111/ans.13648  0.313
2016 Malouf P, Gibbs P, Shapiro J, Sockler J, Bell S. Australian contemporary management of synchronous metastatic colorectal cancer. Anz Journal of Surgery. PMID 27122066 DOI: 10.1111/ans.13619  0.304
2016 Teloken PE, Ransom D, Faragher I, Jones I, Gibbs P, Platell C. Recurrence in patients with stage I colorectal cancer. Anz Journal of Surgery. 86: 49-53. PMID 26235683 DOI: 10.1111/ans.13254  0.338
2015 Wong SF, Wong HL, Field KM, Kosmider S, Tie J, Wong R, Tacey M, Shapiro J, Nott L, Richardson G, Cooray P, Jones I, Croxford M, Gibbs P. Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. Clinical Colorectal Cancer. PMID 26803709 DOI: 10.1016/j.clcc.2015.12.010  0.31
2015 Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JJ, Gibbs P, James B, Powis G, Nolop KB, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26460303 DOI: 10.1200/JCO.2015.63.2497  0.307
2015 Jorissen RN, Christie M, Mouradov D, Sakthianandeswaren A, Li S, Love C, Xu ZZ, Molloy PL, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Burgess AW, ... ... Gibbs P, et al. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. British Journal of Cancer. 113: 979-88. PMID 26305864 DOI: 10.1038/Bjc.2015.296  0.305
2015 Bae S, Wong HL, Tie J, Desai J, Field K, Kosmider S, Fourlanos S, Jones I, Skinner I, Gibbs P. Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. Journal of Cancer Epidemiology. 2015: 189132. PMID 26074965 DOI: 10.1155/2015/189132  0.318
2015 Roohullah A, Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J, Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, et al. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World Journal of Gastroenterology : Wjg. 21: 5352-8. PMID 25954110 DOI: 10.3748/wjg.v21.i17.5352  0.34
2015 Turner N, Tran B, Tran PV, Sinnathamby M, Wong HL, Jones I, Croxford M, Desai J, Tie J, Field KM, Kosmider S, Bae S, Gibbs P. Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. Clinical Colorectal Cancer. PMID 25882598 DOI: 10.1016/j.clcc.2015.02.004  0.301
2015 Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Farragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, ... ... Gibbs P, et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncologica (Stockholm, Sweden). 54: 487-92. PMID 25549537 DOI: 10.3109/0284186X.2014.990158  0.323
2015 Field K, Shapiro J, Wong HL, Tacey M, Nott L, Tran B, Turner N, Ananda S, Richardson G, Jennens R, Wong R, Power J, Burge M, Gibbs P. Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice. Internal Medicine Journal. 45: 267-74. PMID 25403925 DOI: 10.1111/imj.12643  0.305
2015 Tay RY, Jamnagerwalla M, Steel M, Wong H, McKendrick JJ, Faragher I, Kosmider S, Hastie I, Desai J, Gibbs P, Wong R. Survival impact of adjuvant chemotherapy for resected early-stage rectal adenocarcinoma. Journal of Clinical Oncology. 33: 712-712. DOI: 10.1200/jco.2015.33.3_suppl.712  0.306
2015 Lee M, Turner NH, Wong H, Aung SY, RAi R, Maddison C, Morris K, Nott LM, Yip D, Field KM, Shapiro JD, Tie J, Tran B, Wong R, Ananda S, ... ... Gibbs P, et al. Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia. Journal of Clinical Oncology. 33: e14648-e14648. DOI: 10.1200/JCO.2015.33.15_SUPPL.E14648  0.334
2014 Wong H, Field K, Lomax AJ, Tacey M, Shapiro J, McKendrick J, Zimet A, Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, ... ... Gibbs P, et al. 513PIMPACT OF TUMOUR SITE ON BEVACIZUMAB EFFICACY IN METASTATIC COLORECTAL CANCER (MCRC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv173-iv174. PMID 28171914 DOI: 10.1093/annonc/mdu333.16  0.306
2014 Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy. 14: 1477-93. PMID 25138900 DOI: 10.1586/14737140.2014.949678  0.339
2014 Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, ... ... Gibbs P, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 6: 224ra24. PMID 24553385 DOI: 10.1126/Scitranslmed.3007094  0.338
2014 Saxena A, Bester L, Shan L, Perera M, Gibbs P, Meteling B, Morris DL. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. Journal of Cancer Research and Clinical Oncology. 140: 537-47. PMID 24318568 DOI: 10.1007/s00432-013-1564-4  0.314
2014 Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 744-53. PMID 24218517 DOI: 10.1158/1078-0432.Ccr-13-0606  0.334
2014 Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, ... ... Gibbs P, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. The Journal of Pathology. 232: 199-209. PMID 24122236 DOI: 10.1002/path.4287  0.337
2014 Kothari N, Kim RD, Gibbs P, Yeatman TJ, Schell MJ, Desai J, Tie J, Lipton LR, Jorissen RN, Wong H, Sieber O, Day F, Faragher I, Jones I, Tran B. Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 32: 386-386. DOI: 10.1200/jco.2014.32.3_suppl.386  0.316
2014 Lomax A, Wong H, Field KM, Harold M, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Tie J, Kosmider S, Parente P, Lim L, ... ... Gibbs P, et al. Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer. Journal of Clinical Oncology. 32: e14518-e14518. DOI: 10.1200/jco.2014.32.15_suppl.e14518  0.305
2014 Cosgrove LJ, Fung K, Priebe I, Purins L, Tabor B, Buckley M, Pompeia C, Brierley G, Nice E, Adams T, Gibbs P, Tie J, Ruszkiewicz A, Moore J, Lockett T, et al. Abstract 4099: Doctor Cancer Research. 74: 4099-4099. DOI: 10.1158/1538-7445.Am2014-4099  0.322
2013 Bae S, Asadi M, Jones I, McLaughlin S, Bui A, Steele M, Tie J, Gibbs P. Second primary colorectal cancer in the era of prevalent screening and imaging. Anz Journal of Surgery. 83: 963-7. PMID 23528160 DOI: 10.1111/ans.12136  0.313
2013 Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastinâ„¢) [ASCENT]. Bmc Cancer. 13: 120. PMID 23497305 DOI: 10.1186/1471-2407-13-120  0.326
2013 Wong HL, Gibbs P. Does adjuvant chemotherapy in elderly patients with stage III colon cancer really save lives? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 511-2. PMID 23269993 DOI: 10.1200/JCO.2012.45.7770  0.318
2012 Voskoboynik M, Bae S, Ananda S, Desai J, Kosmider S, Gibbs P. An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 23: 2633-2637. PMID 22734008 DOI: 10.1093/ANNONC/MDS184  0.314
2011 Bae S, Asadi M, Millar JL, Jones I, McLaughlin S, Bui A, Steele M, Chao MW, English D, Gibbs P. An analysis of colorectal cancer (CRC) following a diagnosis of prostate cancer (CaP): Is it due to earlier diagnosis or increased incidence? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1560. PMID 28024025 DOI: 10.1200/jco.2011.29.15_suppl.1560  0.302
2011 Michael M, Tebbutt NC, Gibbs P, Lipton LR, Jefford M, Milner A, Gouillou M, Hatzimihalis A, McArthur GA, Zalcberg JR. A phase I trial of imatinib (IM) plus mFOLFOX-bevacizumab in patients with advanced colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14119. PMID 28023186 DOI: 10.1200/jco.2011.29.15_suppl.e14119  0.31
2011 Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 117: 4623-32. PMID 21456008 DOI: 10.1002/cncr.26086  0.311
2011 Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. International Journal of Cancer. Journal International Du Cancer. 128: 2075-84. PMID 20635392 DOI: 10.1002/Ijc.25555  0.306
2010 Moore M, Gibbs P. Adjuvant chemotherapy use among older patients with stage III colon cancer. Jama. 303: 2353; author reply 2. PMID 20551402 DOI: 10.1001/jama.2010.775  0.308
2010 Kosmider S, Shedda S, Jones IT, McLaughlin S, Gibbs P. Predictors of clinic non-attendance: opportunities to improve patient outcomes in colorectal cancer. Internal Medicine Journal. 40: 757-63. PMID 19460064 DOI: 10.1111/j.1445-5994.2009.01986.x  0.305
2009 Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. Journal of the National Cancer Institute. 101: 1182-92. PMID 19666851 DOI: 10.1093/jnci/djp232  0.306
2009 Mishra S, Jones IT, Gibbs P, Shedda S. CR37P�UNREVERSED STOMAS IN RECTAL CANCER Anz Journal of Surgery. 79: A16-A17. DOI: 10.1111/J.1445-2197.2009.04915_36.X  0.312
2009 Shedda SM, Hayes I, Jones IT, Hastie I, Gibbs P. CR26P�LAPAROSCOPIC HYBRID RECTAL RESECTION FOR RECTAL CANCER Anz Journal of Surgery. 79: A14-A14. DOI: 10.1111/J.1445-2197.2009.04915_26.X  0.302
2009 Shimokawa K, Shedda S, Pem A, Jones I, Gibbs P. CR25P�FAILURE TO ATTEND FOLLOW UP APPOINTMENTS IN PATIENTS WITH COLORECTAL CANCER - HOW COMMONLY DOES IT OCCUR AND WHY? Anz Journal of Surgery. 79: A14-A14. DOI: 10.1111/J.1445-2197.2009.04915_25.X  0.342
2008 Tan TH, Kosmider S, Yip D, Gibbs P. Clinical experience of selective internal radiation therapy in combination with systemic chemotherapy as first-line therapy in patients with unresectable hepatic metastases from colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 15080. PMID 27950332 DOI: 10.1200/jco.2008.26.15_suppl.15080  0.316
2008 Field KM, Kosmider S, Jefford M, Jennens R, Green M, Gibbs P. Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? Journal of Oncology Practice / American Society of Clinical Oncology. 4: 271-6. PMID 20856756 DOI: 10.1200/JOP.0852002  0.331
2008 Gibbs P, Handolias D, McLaughlin S, Chapman M, Johns J, Faragher I. Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer. Internal Medicine Journal. 38: 265-9. PMID 18298558 DOI: 10.1111/j.1445-5994.2007.01520.x  0.331
2008 Kosmider S, Field K, Jefford M, Jennens R, Gibbs P. Surveillance following treatment for colorectal cancer in Australia. Has best practice been adopted by medical oncologists? Internal Medicine Journal. 38: 415-21. PMID 17725608 DOI: 10.1111/j.1445-5994.2007.01482.x  0.311
2007 Lim L, Chao M, Shapiro J, Millar JL, Kipp D, Rezo A, Fong A, Jones IT, McLaughlin S, Gibbs P. Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. Diseases of the Colon and Rectum. 50: 2032-9. PMID 17896138 DOI: 10.1007/s10350-007-9062-x  0.318
2007 Field K, Kosmider S, Jefford M, Jennens R, Green M, Gibbs P. 3066 POSTER Exploring first line chemotherapy options in metastatic colorectal cancer (mCRC): nationwide heterogeneity in patient management European Journal of Cancer Supplements. 5: 256. DOI: 10.1016/S1359-6349(07)70994-1  0.321
2006 Gibbs P, McLaughlin S, Skinner I, Jones I, Hayes I, Chapman M, Johns J, Lim L, Faragher I. Re: Completion of therapy by Medicare patients with stage III colon cancer. Journal of the National Cancer Institute. 98: 1582. PMID 17077360 DOI: 10.1093/jnci/djj416  0.303
2006 Thomson BN, Banting SW, Gibbs P. Pancreatic cancer - current management. Australian Family Physician. 35: 212-7. PMID 16642237  0.313
2005 Chao M, Gibbs P, Tjandra J, Cullinan M, McLaughlin S, Faragher I, Skinner I, Jones I. Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer. Anz Journal of Surgery. 75: 286-91. PMID 15932438 DOI: 10.1111/j.1445-2197.2005.03348.x  0.304
Show low-probability matches.